AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00591409
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After induction of anesthesia an intubation dose of NMBA was administered IV: either 0.9 mg/kg rocuronium or 0.1 mg/kg vecuronium.~Maintenance doses of 0.1-0.2 mg/kg rocuronium IV or 0.02-0.04 mg/kg vecuronium IV could be administered if necessary.~At reappearance of T2 the randomized single dose of placebo IV was administered
Trial: NCT02036255
Drug: Taurolidine Heparin
RxNorm normalized name: heparin / taurolidine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02392572
Drug: Akt/ERK Inhibitor ONC201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01870648
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible children will receive one dose of an oral disintegrating Placebo (sugar pill) tablet. Subsequent therapy will be in accordance with World Health Organization guidelines as dictated by the child's hydration status.
Trial: NCT02974725
Drug: LTT462
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LTT462 will be supplied as hard gelatin capsule for oral use.
Trial: NCT01970722
Drug: Pegylated Liposomal Doxorubicin Hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IP or IV
Trial: NCT00874497
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for 104 weeks (2 years)
Trial: NCT02689466
Drug: [18F]FP-TZTP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: radioligand
Trial: NCT00330681
Drug: MCI-186
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two ampoules (60 mg) of MCI-186 injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).
Trial: NCT04620369
Drug: Placebo Administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Instill isotonic nasal saline intranasally
Trial: NCT00067093
Drug: SanOrg34006
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00067093
Drug: LMW heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00067093
Drug: Vitamin K antagonist (VKA)
RxNorm normalized name: Vitamin K antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00134147
Drug: Inhaled Insulin
RxNorm normalized name: insulin, regular, human Inhalation Powder [Afrezza]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03540758
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-diabetic participants will receive placebo and undergo the pancreatic clamp study.~T2D participants will have their blood sugar levels normalized, and will then receive a taste-matched placebo for diazoxide before undergoing the pancreatic clamp study.
Trial: NCT00142038
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00087555
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo one of two doses matching active treatment by volume for 8 weeks.
Trial: NCT01212484
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The trial will be divided into two consecutive, but independent parts. Phase 1, will address the safety and tolerability of carbidopa in patients with FD using an open-label dose titration phase followed by 4-weeks of open-label treatment. Phase 2, will address the efficacy of carbidopa for the treatment of nausea in patients with FD using a randomized, placebo controlled, double blind, 4-week cross over design.
Trial: NCT01290783
Drug: Irintoecan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Irinotecan, 180 mg/m2 IV, over 90 minutes, day 1 (in patients \> 75 years of age, the irinotecan dose in must be reduced to 150 mg/m2).~* Leucovorin, 400 mg/m2, or levoleucovorin, 200 mg/m2, IV over 90 minutes with irinotecan.~* 5-FU, 400 mg/m2 IV bolus day 1, then 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46-48 hours) continuous infusion.~* Repeat every two weeks.~* 8 months of treatment.
Trial: NCT03816891
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: solution for injection
Trial: NCT01246219
Drug: GH treatment (Genotropin)
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 years treatment with GH
Trial: NCT01246219
Drug: 1 year treatment with placebo followed by optional 3 years of GH treatment
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 year treatment with placebo followed by optional 3 years of GH treatment
Trial: NCT03688022
Drug: PPI
RxNorm normalized name: PPIase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton pump inhibitor
Trial: NCT02218775
Drug: LY2456302
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mood and Anxiety Disorders
Trial: NCT02778906
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of the comparator s.c. weekly in comparable to verum
Trial: NCT00613288
Drug: Testosterone (Testogel), GnRH analog (Leuprorelide) and Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The trial is a double blinded, randomised cross-over study of 4 x 2 days with an interval of 1 month in between. 12 healthy young male participants will receive the GnRH-agonist leuprorelide 7,5 mg s.c. 3 weeks before examination on 3 occasions, and a fourth day without intervention.~The four days will include treatment on the examination day, Day 1 with:~1. Placebo (hypogonadism after leuprorelide injection)~2. Testosterone gel 50 mg applicated in the morning at 06.00 am (physiologic substitution - after leuprorelide injection).~3. Testosterone gel 150 mg applicated in the morning at 06.00 am (supra-physiologic substitution - after leuprorelide injection).~4. No treatment.
Trial: NCT01149876
Drug: Tretinoin cream 0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thin layer of tretinoin applied to face.
Trial: NCT01438515
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100mg po twice daily x 7 days
Trial: NCT02220777
Drug: ASP8477
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT02220777
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT01729923
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT01729923
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT02057263
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 4 doses of placebo during the course of the study.
Trial: NCT03020056
Drug: Phacolin eye drops
RxNorm normalized name: Hycolin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After enrollment, the participants will be provided antioxidant eye drops, Phacolin (Zhongshan ophthalmic center, China) for free.The eye drops will be administered 4 times per day for 1 year.Then either phacoemulsification or manual small incision cataract surgery will be performed.
Trial: NCT03374475
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All participants will receive matching placebo capsule during lead in period, treatment period and withdrawal period.
Trial: NCT02558270
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00744328
Drug: Transdermal Estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estradiol patch ranging in dose from 50 to 200 mcg/day
Trial: NCT02252614
Drug: naproxen sodium codein
RxNorm normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pain intensity, contramal consumption
Trial: NCT02252614
Drug: paracetamol codein
RxNorm normalized name: codeine and paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pain intensity, contramal consumption
Trial: NCT02252614
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pain intensity, contramal consumption
Trial: NCT00818363
Drug: SABER-Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injectable Solution; 5.0 mL SABER-Placebo/Once
Trial: NCT00700063
Drug: PEP005 Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.005%, two days treatment
Trial: NCT00700063
Drug: PEP005 Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.01%, two days treatment
Trial: NCT02186080
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00700063
Drug: PEP005 Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.015%, two days treatment
Trial: NCT01536041
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match ONO-6950 tablets or leukotriene receptor antagonist (LTRA) tablets dosed in a similar manner
Trial: NCT00700063
Drug: PEP005 Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.005%, three days treatment
Trial: NCT00700063
Drug: PEP005 Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.01%, three days treatment
Trial: NCT00700063
Drug: Vehicle gel
RxNorm normalized name: vehicle gel base no.61
FDA approved: no
EMA approved: no
PMDA approved: no
Description: three days treatment
Trial: NCT03011905
Drug: EtoriCoxib
RxNorm normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Premedication and first 2 postoperative days.
Trial: NCT02269917
Drug: D/C/F/TAF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily single-tablet regimen containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg.
Trial: NCT02269917
Drug: Boosted Protease Inhibitor (bPI)
RxNorm normalized name: Protease inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Boosted protease inhibitor (limited to darunavir \[DRV\] or atazanavir with low-dose ritonavir \[rtv\] or cobicistat \[COBI\], or lopinavir with rtv) as per current treatment regimen.
Trial: NCT02269917
Drug: FTC/TDF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF).
Trial: NCT00613132
Drug: Gleevec, RAD001, and Hydroxyurea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose of Gleevec will be 400 mg in 1st cohort \& will be increased to 600 mg po/day \& then to 400 mg bid in successive cohorts. Prescribed dose should be administered orally, w large glass of water. Pts should not eat large or high fat meal within 1 hour before or after gleevec dosing. Doses of 600 mg or less should be administered once daily, whereas doses greater than 600 mg should be administered as equal doses twice day. It is recommended that pts take their prescribed Gleevec at same time that they take their prescribed RAD001 \& hydroxyurea, however, 30-60 minute interval between agents is acceptable if required for practical or other compliance issues.
Trial: NCT03459612
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT00097669
Drug: Active VITATOPS Tablet (folic acid 2mg, B6 25mg , B12 500ug) or placebo
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multivitamin
Trial: NCT00303563
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: po qd
Trial: NCT01180790
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Powder in capsule once daily
Trial: NCT02183077
Drug: Meloxicam gel
RxNorm normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02183077
Drug: Meloxicam tablet
RxNorm normalized name: Meloxicam Tablets
DrugBank: Meloxicam (DB00814)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00692640
Drug: XL147 (SAR245408)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gelatin capsules supplied in 25-mg and 100-mg strengths; daily dosing for 21 days/7 days off
Trial: NCT01393613
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, once daily, for six weeks
Trial: NCT00330681
Drug: Placebo of MCI-186
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two ampoules of placebo injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).
Trial: NCT02598934
Drug: Ibandronate
RxNorm normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive oral ibandronate, 150 mg once weekly, for approximately 6 months.
Trial: NCT03955354
Drug: SHR1210
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody
Trial: NCT00344253
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00791297
Drug: CDB-2914
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contraceptive Vaginal Rings delivering a daily dose of 1500 or 2500 μg of CDB-2914
Trial: NCT04513275
Drug: non-medicine intervention
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rating by MCCB only one time
Trial: NCT00004847
Drug: ([18F]-DOPA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: is L 3, 4 dihydroxyphenylalanine (L-DOPA) labeled with the radioactive isotope 18F. In general, PPGLs belong to the group of neuroendocrine tumors. This heterogeneous group of tumors takes up amino acids, transforms them into biogenic amines (dopamine and serotonin) by decarboxylation and stores the amines in vesicles. L DOPA is a precursor of catecholamines (dopamine, norepinephrine and epinephrine). Epinephrine conversion to dopamine is catalyzed by the aromatic amino acid decarboxylase. According to previous and current studies, \[18F\]-DOPA PET is highly sensitive and specific for detection of PHEO/PGL67-69. However, there are only a few reports in the literature using \[18F\]-DOPA as a PET agent and particularly for patients with metastatic PPGLs. PET imaging will be done together with either a CT, an MRI or both modalities.
Trial: NCT00004847
Drug: ([18F]-6F-DA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: is an imaging agent developed at the NIH, that may improve specificity and sensitivity in the localization of PPGLs. \[18F\]-6F-DA enters cells via the membrane norepinephrine transporter. Once inside cells, \[18F\]-6F-DA is translocated via the vesicular monoamine transporter into storage vesicles, where the radioactivity is concentrated. After injection of \[18F\]-6F-DA, the much faster disappearance of \[18F\]-6F-DA-derived radioactivity from the bloodstream and non-neuronal cells than from chromaffin cells should enable rapid visualization of PPGLs by PET scanning.
Trial: NCT01004029
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly intramuscular injections of 1 mL vehicle inert oil until 36 weeks, 6 days of gestation or delivery, whichever occurs first.
Trial: NCT02383238
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral for 6 weeks
Trial: NCT04804059
Drug: [14C]-APX001 Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total dose containing NMT 3.1 MBq (84.0 µCi) 14C
Trial: NCT04804059
Drug: [14C]-APX001 Solution for Infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total dose containing NMT 3.4 MBq (93.0 µCi) 14C
Trial: NCT04278495
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02517528
Drug: ABT-333
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT02326350
Drug: Lactose powder
RxNorm normalized name: Lactose Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02311777
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be given orally during preoperative period
Trial: NCT00386308
Drug: Placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01941992
Drug: SAMITAL®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01941992
Drug: Placebo sachets
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00590070
Drug: adenosine
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adenosine (80 mcg as fast bolus followed by 2 mg given in 33cc of saline in 2 minutes as slow bolus)
Trial: NCT00590070
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 33 cc of heparinized saline given in 2 minutes as slow bolus
Trial: NCT00663117
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02209636
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Table identical to lanthanum carbonate but with no active ingredient
Trial: NCT02209636
Drug: Ascorbic Acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous administration during measurement of flow mediated dilation.
Trial: NCT01644188
Drug: Placebo (for alirocumab)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mL subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using the autoinjector.
Trial: NCT01644188
Drug: Placebo (for ezetimibe)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One capsule once daily orally at approximately the same time of the day with or without food.
Trial: NCT01644188
Drug: Lipid Modifying Therapy (LMT)
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose.
Trial: NCT01310712
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo twice a day for 42 days.
Trial: NCT02475876
Drug: Clindamycin
RxNorm normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Route of administration is IV for all Cohorts. Dosing interval is every 8 hrs. for all Cohorts:~* Cohort 1; No. Subjects = 5; Age 1-5 months; Dose = 9 mg/kg;~* Cohort 2; No. Subjects = 5; Age \>5 months to 1 year; Dose =12 mg/kg;~* Cohort 3; No. Subjects = 5; Age \>1-2 years; Dose =12 mg/kg.~* Cohort 4; No. Subjects = 4; Age \>2-6 years; Dose =12 mg/kg.~* Cohort 5; No. Subjects = 4; Age \>6-12 years; Dose =10 mg/kg.~* Cohort 6; No. Subjects = 4; Age \>12-16 years; Dose =10 mg/kg.
Trial: NCT02742532
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal saline solution
Trial: NCT02151643
Drug: PT20
RxNorm normalized name: GALACTIC PURPLE TETRA TRANSGENIC WHOLE (PT2013 RDNA CONSTRUCT)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified ferric oxide adipate tablets
Trial: NCT00508274
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine is supplied as a biconvex, oblong, light peach and peach colored, film-coated tablets for oral administration.
Trial: NCT00526097
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-to-match bisacodyl 10 mg (2 x 5 mg) once daily
Trial: NCT04591262
Drug: 14C-PF-06826647 100 ug IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14C-PF-06826647 100 ug IV
Trial: NCT01709123
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pill for chromium niacinate
Trial: NCT01660919
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01660919
Drug: rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00038298
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo given 3 times weekly
Trial: NCT00038298
Drug: AGM 719
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg 3 times weekly
Trial: NCT00038298
Drug: placebo to AMG 719
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo dose given 3 times weekly
Trial: NCT02547519
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total of 12 months treatment; daily treatment with insulin or placebo capsules containing filling substance (microcrystalline cellulose).
Trial: NCT03639922
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tablets of placebo per day for 6 days
Trial: NCT03444467
Drug: NNC9204-1513
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive NNC9204-1513 subcutaneous (s.c., in to a skin fold on the stomach) injection as single increasing doses of 0.01 mg, 0.04 mg, 0.10 mg, 0.25 mg, 0.50 mg, 1.0 mg or 2.0 mg. Each participant will only be given one dose.~Dose escalation will proceed to the next planned dose level if there are no safety concerns raised by the investigator or by the trial safety group.
Trial: NCT03444467
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive single dose of placebo (for double dummy injections).
Trial: NCT03401918
Drug: Oral antibiotics and vaginal probiotics
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For subjects with abnormal microbiome results, oral antibiotics and vaginal probiotic treatment will be offered followed by a repeat uterine microbiome biopsy.